The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Cognitive decline in Parkinson disease
Open accessAbstract
Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD). In recent years, research has focused on the pre-dementia stages of cognitive impairment in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of cognition - or even reversal to normal cognition - is not uncommon. In addition to limbic and cortical spread of Lewy pathology, several other mechanisms are likely to contribute to cognitive decline in PD, and a variety of biomarker studies, some using novel structural and functional imaging techniques, have documented in vivo brain changes associated with cognitive impairment. The evidence consistently suggests that low cerebrospinal fluid levels of amyloid-β 42, a marker of comorbid Alzheimer disease (AD), predict future cognitive decline and dementia in PD. Emerging genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Cognitive enhancing medications have some effect in PD dementia, but no convincing evidence that progression from MCI to dementia can be delayed or prevented is available, although cognitive training has shown promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–216 of 216
Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease
Beyer, M. K., Alves, G. W., Hwang, K., Babakchanian, S., Brønnick, K., Chou, Y., Dalaker, T. O., Kurz, M. W., Larsen, J. O., Somme, J. H., et al. (2013) · Movement Disorders · doi:10.1002/mds.25282 · Cited by 28
Genomic determinants of motor and cognitive outcomes in Parkinson’s disease
Chung, S. J., Armasu, S. M., Biernacka, J. M., Anderson, K. J., Lesnick, T. G., Rider, D. N., Cunningham, J. M., Ahlskog, J. E., Frigerio, R., & Maraganore, D. M. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.04.025 · Cited by 28
Synaptic Protein Alterations in Parkinson’s Disease
Pienaar, I. S., Burn, D. J., Morris, C. M., & Dexter, D. T. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8226-9 · Cited by 28
Akhtar, R. S., Xie, S. X., Brennan, L., Pontecorvo, M. J., Hurtig, H. I., Trojanowski, J. Q., Weintraub, D. A., & Siderowf, A. D. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12290 · Cited by 28
Self-citationLin, W.-C., Chen, P.-C., Huang, Y., Tsai, N., Chen, H.-L., Wang, H., Lin, T., Chou, K., Chen, M., Chen, Y.-W., et al. (2016) · Medicine · doi:10.1097/md.0000000000002206 · Cited by 28
Cholinergic Deficit and Response to Donepezil Therapy in Parkinson’s Disease with Dementia
Hiraoka, K., Okamura, N., Funaki, Y., Hayashi, A., Tashiro, M., Hisanaga, K., Fujii, T., Takeda, A., Yanai, K., Iwata, R., et al. (2012) · European Neurology · doi:10.1159/000338774 · Cited by 28
Varrone, A., Svenningsson, P., Marklund, P., Fatouros‐Bergman, H., Forsberg, A., Halldin, C., Nilsson, L., & Farde, L. (2015) · Synapse · doi:10.1002/syn.21823 · Cited by 27
Song, I., Kim, Y., Cho, H.-J., Chung, S., & Chung, Y. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31824acd84 · Cited by 25
Brain Volumetric Correlates of Memory in Early Parkinson's Disease
Ellfolk, U., Joutsa, J., Rinne, J. O., Parkkola, R. K., Jokinen, P., & Karrasch, M. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130276 · Cited by 24
Clinical EEG in cognitively impaired patients with Parkinson's Disease
Schlede, N., Zimmermann, R., Ehrensperger, M. M., Gschwandtner, U., Hardmeier, M., Hatz, F., Monsch, A. U., Naegelin, Y., & Fuhr, P. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.034 · Cited by 22
Seidel, K., Schöls, L. J., Nuber, S., Petrasch‐Parwez, E., Gierga, K., Wszołek, Z. K., Dickson, D. W., Gai, W., Bornemann, A., Rieß, O., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22078 · Cited by 21
Relationship of the Ubiquilin 1 gene with Alzheimer's and Parkinson's disease and cognitive function
Vásquez, A. A., de Lau, L., Pardo, L. M., Liu, F., Feng, B., Bertoli‐Avella, A. M., Isaacs, A. J., Aulchenko, Y. S., Albert Hofman, D., Oostra, B. A., et al. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.07.015 · Cited by 17
Chiaravalloti, A., Stefani, A., Fiorentini, A., Lacanfora, A., Stanzione, P., & Schillaci, O. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2841-4 · Cited by 14
Impaired cognitive performance and hippocampal atrophy in Parkinson disease
Yıldız, D., Erer, S., Zarifoğlu, M., Hakyemez, B., Bakar, M., Karlı, N., Varlıbaş, Z. N., & Tufan, F. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1408-68 · Cited by 14
Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture
Bajic, N., Jenner, P. G., Ballard, C. G., & Francis, P. T. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0816-9 · Cited by 10
Self-citationWaldvogel (1999) · doi:10.1002/1531-8249(199907)46:1
Flagged first, then by citations
Cited by
Sorted by citations
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
BackgroundHallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J. J., & Tan, E. K. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,273
Allocati, N., Masulli, M., Di Ilio, C., & Federici, L. (2018) · Oncogenesis · doi:10.1038/s41389-017-0025-3 · Cited by 625
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Metadata
- Authors
- Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C.
- Affiliations
- King's College London (GB)
- Corresponding author
- Aarsland, Dag
- Venue
- Nature Reviews Neurology
- Published
- 2017-03-03
- Volume
- 13
- Issue
- 4
- Pages
- 217-231
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC5643027
- OpenAlex
- W2593272776
- Cited by
- 1,027
- References
- 216
- Citations by year
- 2026: 102 · 2025: 99 · 2024: 138 · 2023: 104 · 2022: 105 · 2021: 171 · 2020: 116 · 2019: 89 · 2018: 68 · 2017: 33
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- South London and Maudsley NHS Foundation Trust
- National Institute for Health and Care Research
- King's College London
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, cognitive decline, Parkinson's disease dementia, mild cognitive impairment, cerebrospinal fluid biomarkers, amyloid-beta 42, Lewy body pathology, APOE ε4, GBA mutations, cognitive training, nootropic drugs
- MeSH terms
- Dementia, Humans, Parkinson Disease, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
